NCT02941549已完成2 期
A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase IIa Study To Assess The Safety And Efficacy Of Orally Administered Epeleuton In NAFLD Patients.
Afimmune16 个研究点 分布在 3 个国家目标入组 96 人开始时间: 2016年12月20日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 96
- 试验地点
- 16
- 主要终点
- Change in Serum ALT (Alanine Aminotransferase) From Baseline to Week 16
研究概览
简要总结
The purpose of this randomised, double-blind, placebo-controlled, parallel group study is to assess the safety and efficacy of orally administered Epeleuton capsules versus placebo in the treatment of adult patients with Non Alcoholic Fatty Liver Disease (NAFLD)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients diagnosed with NAFLD by the presence of hepatic steatosis on imaging or histology in the absence of any secondary causes.
- •Patients with an ALT ≥ 1.5 upper limit of normal (ULN) and < 5 ULN on two occasions 7 or more days apart during screening.
- •Patients with historical liver biopsy showing NASH and/or ≥ F1 fibrosis OR NFS ≥ -1.455 OR Fib- 4 ≥ 1.3 OR Fibroscan ≥8kPa within 3 months of screening.
- •Patients with a body mass index (BMI) between 25.0 and 40.0 kg/m² inclusive. Patients with a history of controlled obesity or controlled diabetes are allowed on the study.
- •Patients whose pre-study clinical laboratory findings do not interfere with their participation in the study, in the opinion of the Investigator.
- •Patients aged between 18 and 75 years inclusive.
- •Female patients and male patients with female partners of child bearing potential must use adequate contraception or have a sterilized partner for the duration of the study. Adequate contraception is defined as: systemic hormonal contraceptives; intrauterine device or barrier method of contraception in conjunction with spermicide; or agree to sexual abstinence, defined as a patient refraining from heterosexual intercourse during the entire period of risk associated with the study treatments and in line with their preferred and usual lifestyle. Hormonal contraceptives must be on a stable dose for at least one month before baseline.
- •Patients who are able to communicate well with the Investigator, to understand and comply with the requirements of the study, and understand and sign the written informed consent.
排除标准
- •Patients with an unstable metabolic condition such as weight change > 5% in the 3 months prior to inclusion.
- •Patients with medical/surgical history of gastric bypass surgery, orthotopic liver transplant (OLT) or listed for OLT.
- •Patients with uncontrolled diabetes mellitus type 2, i.e. HbA1c ≥ 9% (75 mmol/mol) at the time of screening.
- •Patients with decompensated or severe liver disease as evidenced by one or more of the following: confirmed cirrhosis or suspicion of cirrhosis, esophageal varices, ascites, suspicion of portal hypertension, hospitalization for liver disease within 60 days of screening, bilirubin ≥ 2 x ULN, or ALT or AST ≥ 5 x ULN. Patients with Gilbert's syndrome are eligible if the conjugated bilirubin is ≤ 1.5 x ULN.
- •Patients with inflammatory bowel disease that is either active or requiring medical therapy.
- •Patients with diagnosed or suspected autoimmune diseases such as systemic lupus erythematosus and/or rheumatoid arthritis.
- •Patients with a history of or active non-liver malignancies other than curatively treated skin cancer (basal cell or squamous cell carcinomas).
- •Patients with a significant systemic or major illness other than liver disease, including coronary artery disease, cerebrovascular disease, pulmonary disease, renal insufficiency, serious psychiatric disease, respiratory or hypertensive disease, as well as diabetes and arthritis that, in the opinion of the Investigator, would preclude the patient from participating in and completing the study.
- •Patients requiring anti-diabetic treatment (including insulin sensitizing agents), and/or lipid lowering treatment, and who are not on a stable dose for at least 3 months prior to screening should be excluded. If patients are insulin dependent this treatment should have commenced at least 3 months prior to screening, however changes in dose are permitted.
- •Patients with known hypersensitivity to any ingredients of the study treatment.
- •Patients with a positive test for human immunodeficiency virus antibodies, Hepatitis B surface antigen or Hepatitis C antibodies at screening.
- •Patients with liver disease of other etiologies such as drug-induced, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, haemochromatosis, alpha-1 antitrypsin deficiency or Wilson's disease.
- •Patients with a significant history of drug/solvent abuse, in the opinion of the investigator.
- •Patients with a history of alcohol abuse in the opinion of the Investigator, or who currently drinks in excess of 21 units per week (males) or 14 units per week (females), whereby a unit consists of 10ml or 8mg of pure alcohol.
- •Patients who have used dietary supplements rich in omega-3 or omega-6 fatty acids in the 4 weeks prior to baseline.
- •Patients who have participated in any other clinical study with an investigational drug within 3 months before the first day of administration of study treatment.
- •Patients who are pregnant, planning pregnancy, breastfeeding and/or are unwilling to use adequate contraception (as specified in inclusion criterion 7) during the study.
- •Patients, in the opinion of the Investigator, not suitable to participate in the study.
研究组 & 干预措施
Placebo
Placebo Comparator
2 x placebo 500 mg capsules orally administered twice a day (4 capsules daily) for 16 weeks
干预措施: Placebo capsules (Other)
1000 mg Epeleuton
Experimental
1 x Epeleuton 500 mg capsule and 1 x placebo 500 mg capsule orally administered twice a day (4 capsules daily) for 16 weeks
干预措施: Epeleuton (Drug)
2000 mg Epeleuton
Experimental
2 x Epeleuton 500 mg capsules orally administered twice a day (4 capsules daily) for 16 weeks
干预措施: Epeleuton (Drug)
结局指标
主要结局
Change in Serum ALT (Alanine Aminotransferase) From Baseline to Week 16
时间窗: 16 Weeks
Change in serum ALT from baseline to Week 16 using ANCOVA.
Change in Liver Stiffness Measurements by Transient Elastography From Baseline to Week 16
时间窗: 16 Weeks
To evaluate change in liver stiffness measurements using Transient Elastography from baseline to Week 16 using FibroScan® 502 Touch model or equivalent.
Number of Treatment Emergent Adverse Events (TEAEs) in Each Treatment Group Leading to Treatment Discontinuation
时间窗: 20 Weeks
Subjects with at least 1 TEAE leading to treatment discontinuation
次要结局
- Change in Serum ALT (Alanine Aminotransferase) From Baseline to Weeks 2, 4, 8 and 12(12 Weeks)
- Change in AST (Aspartate Aminotransferase) From Baseline to Weeks 2, 4, 8, 12 and 16(16 Weeks)
- Change in AST:ALT Ratio From Baseline to Weeks 2, 4, 8, 12 and 16(16 Weeks)
- Change in FIB-4 Index From Baseline to Week 16(16 Weeks)
- Change in Non-Alcoholic Fatty Liver Disease (NAFLD) Fibrosis Score (NFS) From Baseline to Week 16(16 Weeks)
- Change in ELF (Enhanced Liver Fibrosis Score) From Baseline to Week 16(16 Weeks)
- Change in HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) From Baseline to Weeks 2, 4, 8, 12 and 16(16 Weeks)
- Change in Adipo-IR (Adipose Tissue Insulin Resistance) From Baseline to Weeks 2, 4, 8, 12 and 16.(16 Weeks)
- Change in Hepatic Fat Measured by CAP (Controlled Attenuation Parameter) From Baseline to Week 16.(16 Weeks)
研究者
研究点 (16)
Loading locations...
相似试验
已完成
2 期
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary DiseaseNCT03414541Afimmune49
Unknown
2 期
EWO1 in Persistent Allergic Rhinitis PatientsRhinitis, Allergic, PerennialNCT00153595China Medical University Hospital60
已完成
3 期
Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic AsthmaticsAsthmaNCT02821416AstraZeneca46
已完成
不适用
A Study to Assess the Gut Health Effects of Oil Compound on Healthy AdultsGut HealthNCT05837754Vedic Lifesciences Pvt. Ltd.102
已完成
1 期
Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of GBS Vaccine in Elderly ParticipantsGroup B Streptococcal InfectionsNCT05782179Minervax ApS90